Cargando…

Treatment of Refractory Metastatic Renal Cell Carcinoma

SIMPLE SUMMARY: The treatment of metastatic renal cell carcinoma continues to rapidly evolve, with various combinations of immune checkpoint inhibitors and targeted tyrosine kinase inhibitors improving outcomes in the first-line setting. However, a significant subset of patients fail to respond to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vento, Joseph A., Rini, Brian I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599552/ https://www.ncbi.nlm.nih.gov/pubmed/36291789 http://dx.doi.org/10.3390/cancers14205005

Ejemplares similares

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2020)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

Emerging Targets in Clear Cell Renal Cell Carcinoma
por: Chen, Yu-Wei, et al.
Publicado: (2022)

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
por: Tucker, Matthew D., et al.
Publicado: (2020)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
por: Morel, Armand, et al.
Publicado: (2010)

New treatment options for metastatic renal cell carcinoma
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2017)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
por: Aeppli, Stefanie, et al.
Publicado: (2020)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
por: Schwandt, Anita, et al.
Publicado: (2009)

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
por: Grimm, Marc-Oliver, et al.
Publicado: (2021)

Biology of Metastatic Renal Cell Carcinoma
por: Milella, Michele, et al.
Publicado: (2011)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Brown, Landon C., et al.
Publicado: (2021)

Sequence of treatment in locally advanced and metastatic renal cell carcinoma
por: Fischer, Stefanie, et al.
Publicado: (2015)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Capecitabine in the treatment of metastatic renal cell carcinoma
por: Oevermann, K, et al.
Publicado: (2000)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
por: Kathuria-Prakash, Nikhita, et al.
Publicado: (2021)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
por: Zahoor, Haris, et al.
Publicado: (2018)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
por: Xu, Kevin Y, et al.
Publicado: (2015)

Update on the treatment of metastatic renal cell carcinoma
por: Medina López, Rafael Antonio, et al.
Publicado: (2022)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
por: Aeppli, S., et al.
Publicado: (2021)

Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma
por: Vaziri, Susan A. J., et al.
Publicado: (2012)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Systemic therapy in metastatic renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2016)

Sequential Therapy in Metastatic Renal Cell Carcinoma
por: Hirsch, Bradford R., et al.
Publicado: (2016)

Novel immunotherapy in metastatic renal cell carcinoma
por: Cho, Yang Hyun, et al.
Publicado: (2017)

Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma
por: Hua, San Hue, et al.
Publicado: (2022)

Resistance to cancer immunotherapy in metastatic renal cell carcinoma
por: Moreira, Marco, et al.
Publicado: (2020)

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
por: Liu, Xiaoyan, et al.
Publicado: (2016)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_observ7oc2jd6nj5e7uui45bvc